Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Trastuzumab Emtansine”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03784599
What this trial is testing

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 28
Testing effectiveness (Phase 2)UnknownNCT06125834
What this trial is testing

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Who this might be right for
Advanced Breast CancerObjective Response RateTrastuzumab Emtansine
The First Affiliated Hospital with Nanjing Medical University 36
Testing effectiveness (Phase 2)Study completedNCT02289833
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 49
Large-scale testing (Phase 3)Study completedNCT02131064
What this trial is testing

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 444
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Early research (Phase 1)Study completedNCT02135159
What this trial is testing

Patients With Brain Metastases From HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle 36
Large-scale testing (Phase 3)Study completedNCT03084939
What this trial is testing

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 351
Testing effectiveness (Phase 2)WithdrawnNCT04351230
What this trial is testing

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2 Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more
Academic and Community Cancer Research United
Post-approval studies (Phase 4)Study completedNCT02658734
What this trial is testing

Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Who this might be right for
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche 70
Testing effectiveness (Phase 2)Looking for participantsNCT04620187
What this trial is testing

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Who this might be right for
Salivary Gland CancerHER2 Gene Mutation
Dana-Farber Cancer Institute 37
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Testing effectiveness (Phase 2)Study completedNCT01853748
What this trial is testing

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 512
Early research (Phase 1)Active Not RecruitingNCT05650879
What this trial is testing

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Who this might be right for
HER2 Mutant Non-small Cell Lung CancerHER2-positive Metastatic Breast CancerHER2 Gene Mutation+1 more
Enliven Therapeutics 198
Testing effectiveness (Phase 2)Study completedNCT00943670
What this trial is testing

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 51
Testing effectiveness (Phase 2)Study completedNCT01565200
What this trial is testing

HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1

Who this might be right for
HER-2 Positive Breast Cancer
Jules Bordet Institute 90
Testing effectiveness (Phase 2)Study completedNCT00934856
What this trial is testing

Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 98
Large-scale testing (Phase 3)Study completedNCT01120184
What this trial is testing

Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,095
Testing effectiveness (Phase 2)Looking for participantsNCT04893109
What this trial is testing

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Dana-Farber Cancer Institute 500
Testing effectiveness (Phase 2)Looking for participantsNCT05388149
What this trial is testing

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Who this might be right for
Breast CancerHER2-positive Breast Cancer
University Health Network, Toronto 15
Testing effectiveness (Phase 2)WithdrawnNCT02725541
What this trial is testing

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

Who this might be right for
Breast Cancer
Jenny C. Chang, MD
Next Page